{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:59:13Z","timestamp":1788998353980,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,4,25]],"date-time":"2013-04-25T00:00:00Z","timestamp":1366848000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s11095-013-1044-1","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T08:53:27Z","timestamp":1367398407000},"page":"1999-2009","source":"Crossref","is-referenced-by-count":28,"title":["Trastuzumab Labeled to High Specific Activity with 111In by Conjugation to G4 PAMAM Dendrimers Derivatized with Multiple DTPA Chelators Exhibits Increased Cytotoxic Potency on HER2-Positive Breast Cancer Cells"],"prefix":"10.1007","volume":"30","author":[{"given":"Conrad","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongli","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond M.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,25]]},"reference":[{"key":"1044_CR1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0959-8049(97)10157-5","volume":"34","author":"F Revillion","year":"1998","unstructured":"Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998;34:791\u2013808.","journal-title":"Eur J Cancer"},{"key":"1044_CR2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719\u201326.","journal-title":"J Clin Oncol"},{"key":"1044_CR3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783\u201392.","journal-title":"N Engl J Med"},{"key":"1044_CR4","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","volume":"17","author":"MA Cobleigh","year":"1999","unstructured":"Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639\u201348.","journal-title":"J Clin Oncol"},{"key":"1044_CR5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10147-006-0575-4","volume":"11","author":"E Tokunaga","year":"2006","unstructured":"Tokunaga E, Oki E, Kojiro N, Koga T, Egashira A, et al. Trastuzumab and breast cancer: developments and current status. Int J Cin Oncol. 2006;11:199\u2013208.","journal-title":"Int J Cin Oncol"},{"key":"1044_CR6","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2967\/jnumed.106.037937","volume":"48","author":"DL Costantini","year":"2007","unstructured":"Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. 111In-labeled trastuzumab (Herceptin) modified with nuclear localizing sequences (NLS): An Auger electron-emitting radiotherapeutic agent for HER2\/neu-amplified breast cancer. J Nucl Med. 2007;48:1357\u201368.","journal-title":"J Nucl Med"},{"key":"1044_CR7","first-page":"1479","volume":"44","author":"AI Kassis","year":"2003","unstructured":"Kassis AI. Cancer therapy with Auger electrons: are we almost there? J Nucl Med. 2003;44:1479\u201381.","journal-title":"J Nucl Med"},{"key":"1044_CR8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0014-4827(87)90319-3","volume":"170","author":"Y Yoneda","year":"1987","unstructured":"Yoneda Y, Arioka T, Imamoto-Sonobe N, Sugawa H, Shimonishi Y, Uchida T. Synthetic peptides containing a region of SV 40 large T-antigen involved in nuclear localization direct the transport of proteins into the nucleus. Exp Cell Res. 1987;170:439\u201352.","journal-title":"Exp Cell Res"},{"key":"1044_CR9","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2967\/jnumed.109.072389","volume":"51","author":"DL Costantini","year":"2010","unstructured":"Costantini DL, McLarty K, Lee H, Done SJ, Vallis KA, Reilly RM. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts. J Nucl Med. 2010;51:1084\u201391.","journal-title":"J Nucl Med"},{"key":"1044_CR10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond EH, Schwartz JN, Hagerty KL, Allred DC, et al. American society of clinical oncology\/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118\u201345.","journal-title":"J Clin Oncol"},{"key":"1044_CR11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/9780470613214.ch2","volume-title":"Monoclonal antibody and peptide-targeted radiotherapy of cancer","author":"RM Reilly","year":"2010","unstructured":"Reilly RM. The radiochemistry of monoclonal antibodies and peptides. In: Reilly RM, editor. Monoclonal antibody and peptide-targeted radiotherapy of cancer. Hoboken: John Wiley & Sons; 2010. p. 39\u2013100."},{"key":"1044_CR12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11095-012-0853-y","volume":"30","author":"AJ Boyle","year":"2013","unstructured":"Boyle AJ, Liu P, Lu Y, Weinrich D, Scollard DA, Ngo Njock Mbong G, et al. The effect of metal-chelating polymers (MCPs) for 111In complexed via the streptavidin-biotin system to trastuzumab Fab fragments on tumor and normal tissue distribution in mice. Pharm Res. 2013;30:104\u201316.","journal-title":"Pharm Res"},{"key":"1044_CR13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/1535-7163.MCT-05-0325","volume":"5","author":"G Wu","year":"2006","unstructured":"Wu G, Barth RF, Yang W, Kawabata S, Zhang L, Green-Church K. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther. 2006;5:52\u20139.","journal-title":"Mol Cancer Ther"},{"key":"1044_CR14","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1021\/bc050348p","volume":"17","author":"R Shukla","year":"2006","unstructured":"Shukla R, Thomas TP, Peters JL, Desai AM, Kukowska-Latallo J, Patri AK, et al. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem. 2006;17:1109\u201315.","journal-title":"Bioconjug Chem"},{"key":"1044_CR15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1021\/bc0341674","volume":"15","author":"G Wu","year":"2004","unstructured":"Wu G, Barth RF, Yang W, Chatterjee M, Tjarks W, Ciesielski MJ, et al. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjug Chem. 2004;15:185\u201394.","journal-title":"Bioconjug Chem"},{"key":"1044_CR16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/9780470613214.ch9","volume-title":"Monoclonal antibody and peptide-targeted radiotherapy of cancer","author":"RM Reilly","year":"2010","unstructured":"Reilly RM, Kassis A. Targeted auger electron radiotherapy of malignancies. In: Reilly RM, editor. Monoclonal antibody and peptide-targeted radiotherapy of cancer. Hoboken: Wiley; 2010. p. 289\u2013348."},{"key":"1044_CR17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00259-008-0923-x","volume":"36","author":"K McLarty","year":"2009","unstructured":"McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging. 2009;36:81\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1044_CR18","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1007\/s002590000293","volume":"27","author":"H Kobayashi","year":"2000","unstructured":"Kobayashi H, Sato N, Saga T, Nakamoto Y, Ishimori T, Toyama S, et al. Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity. Eur J Nucl Med. 2000;27:1334\u20139.","journal-title":"Eur J Nucl Med"},{"key":"1044_CR19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.nucmedbio.2009.10.001","volume":"37","author":"C Chan","year":"2010","unstructured":"Chan C, Cai Z, Su R, Reilly RM. 111In- or 99mTc-labeled recombinant VEGF bioconjugates: in vitro evaluation of their cytotoxicity on porcine aortic endothelial cells overexpressing Flt-1 receptors. Nucl Med Biol. 2010;37:105\u201315.","journal-title":"Nucl Med Biol"},{"key":"1044_CR20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00259-005-1908-7","volume":"33","author":"M Hu","year":"2006","unstructured":"Hu M, Chen P, Wang J, Chan C, Scollard DA, Reilly RM. Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer. Eur J Nucl Med Mol Imaging. 2006;33:301\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1044_CR21","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2967\/jnumed.108.051805","volume":"49","author":"Z Cai","year":"2008","unstructured":"Cai Z, Chen Z, Bailey KE, Scollard DA, Reilly RM, Vallis KA. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF. J Nucl Med. 2008;49:1353\u201361.","journal-title":"J Nucl Med"},{"key":"1044_CR22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1021\/bc700308q","volume":"19","author":"C W\u00e4ngler","year":"2008","unstructured":"W\u00e4ngler C, Moldenhauer G, Eisenhut M, Haberkorn U, Mier W. Antibody-dendrimer conjugates: the number, not the size of the dendrimers, determines the immunoreactivity. Bioconjug Chem. 2008;19:813\u201320.","journal-title":"Bioconjug Chem"},{"key":"1044_CR23","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1021\/mp100105c","volume":"7","author":"T Miyano","year":"2010","unstructured":"Miyano T, Wijagkanalan W, Kawakami S, Yamashita F, Hashida M. Anionic amino acid dendrimer-trastuzumab conjugates for specific internalization in HER2-positive cancer cells. Mol Pharm. 2010;7:1318\u201327.","journal-title":"Mol Pharm"},{"key":"1044_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/cbr.2007.0430","volume":"23","author":"DL Costantini","year":"2008","unstructured":"Costantini DL, Hu M, Reilly RM. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm. 2008;23:3\u201324.","journal-title":"Cancer Biother Radiopharm"},{"key":"1044_CR25","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s11095-005-8330-5","volume":"22","author":"H Kang","year":"2005","unstructured":"Kang H, DeLong R, Fisher MH, Juliano RL. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res. 2005;22:2099\u2013106.","journal-title":"Pharm Res"},{"key":"1044_CR26","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.cr.7290320","volume":"15","author":"QQ Chen","year":"2005","unstructured":"Chen QQ, Chen XY, Jiang YY, Liu J. Identification of novel nuclear localization signal within the ErbB-2 protein. Cell Res. 2005;15:504\u201310.","journal-title":"Cell Res"},{"key":"1044_CR27","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2967\/jnumed.109.063156","volume":"51","author":"Z Cai","year":"2010","unstructured":"Cai Z, Pignol JP, Chan C, Reilly RM. Cellular dosimetry of 111In using Monte Carlo N-particle computer code: comparison with analytic methods and correlation with in vitro cytotoxicit. J Nucl Med. 2010;51:462\u201370.","journal-title":"J Nucl Med"},{"key":"1044_CR28","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.addr.2005.09.019","volume":"57","author":"R Duncan","year":"2005","unstructured":"Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev. 2005;57:2215\u201337.","journal-title":"Adv Drug Deliv Rev"},{"key":"1044_CR29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0168-3659(99)00246-1","volume":"65","author":"N Malik","year":"2000","unstructured":"Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release. 2000;65:133\u201348.","journal-title":"J Control Release"},{"key":"1044_CR30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00004032-197610000-00006","volume":"31","author":"C L\u00fccke-Huhle","year":"1976","unstructured":"L\u00fccke-Huhle C. Proliferation-dependent cytotoxicity of diethylenetriaminepentaacetate (DTPA) in vitro. Health Phys. 1976;31:349\u201354.","journal-title":"Health Phys"},{"key":"1044_CR31","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.bbrc.2004.08.223","volume":"323","author":"M Michaelis","year":"2004","unstructured":"Michaelis M, Langer K, Arnold S, Doerr HW, Kreuter J, Cinatl Jr J. Pharmacological activity of DTPA linked to protein-based drug carrier systems. Biochem Biophys Res Commun. 2004;323:1236\u201340.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-013-1044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-013-1044-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-013-1044-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T05:54:33Z","timestamp":1559368473000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-013-1044-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,25]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["1044"],"URL":"https:\/\/doi.org\/10.1007\/s11095-013-1044-1","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,25]]}}}